Cardinal Health's FY27 EPS Growth Target Fits Bull Case, but Valuation Remains Stretched

What happened

Cardinal Health CEO Jason Hollar told the Morgan Stanley Global Healthcare Conference that fiscal 2027 will extend the company's operating momentum, targeting 13%-15% adjusted EPS growth with all five segments positioned constructively. This commentary aligns with management's recent track record of beat-and-raise quarters and the specialty/MSO platform's expansion, following FY26 guidance of at least $10 in non-GAAP EPS. However, the stock already trades near $214, or roughly 22x that floor and 17.8x EV/EBITDA, embedding sustained double-digit growth and flawless execution. The report's bear case highlights growing gaps between GAAP and non-GAAP earnings, rising leverage from acquisitions, and policy/customer concentration risks that are not addressed by this outlook. While the explicit FY27 target provides some visibility, it does not materially change the risk-reward from a value perspective, as the market has already priced in much of this optimism.

Implication

The explicit FY27 EPS growth target of 13-15% provides a clearer roadmap but is still predicated on non-GAAP adjustments that exclude significant acquisition-related amortization and compensation costs. While the specialty platform shows genuine momentum, the stock's current multiple assumes the bull case plays out with little room for error; any slowdown in specialty margins, an adverse CVS contract development, or deeper IRA price cuts could trigger a sharp de-rating. The news may produce a short-term positive reaction, but from a value standpoint, the risk/reward remains skewed to the downside, and the stock offers limited margin of safety given negative tangible book value. We maintain a hold/sell bias and would use any price spikes to lighten positions, particularly if the stock approaches the $235 trim level identified in the report. A more attractive entry would require a pullback toward $185 or clearer evidence that GAAP earnings are catching up with non-GAAP growth.

Thesis delta

No change to the overall thesis. The news confirms management's confidence in the specialty-led growth algorithm, but this was already reflected in the report's base and bull scenarios. The explicit FY27 EPS growth target is within the range of expectations and does not mitigate the core risks of overvaluation, non-GAAP earnings quality, customer concentration, and policy pressure.